Lectures / Webinars

ICNC2024 Symposia: Neurometabolic Disorders: Current Status and Challenges For Low Middle Income Countries Neurobehavioural and Autism Spectrum Disorders associated with Inborn Errors of Metabolism - current concepts Bithi Debnath

ICNC2024 Symposia: The burden of inherited metabolic disorders in Bangladesh and current research priorities The burden of inherited metabolic disorders in Bangladesh and current research priorities Nazmul Hoque

ICNC2024 Symposia: Addressing The Restrictions and Mortality In The Lives of Children With Epilepsy. Mechanism of SUDEP; Results from recent clinical and basic sciences research Helen Cross

ICNC2024 Symposia: Addressing The Restrictions and Mortality In The Lives of Children With Epilepsy. Restrictions in the lives of Children with Epilepsy: Finding the right balance Jithangi Wanigasinghe

ICNC2026 Symposia: Addressing The Restrictions and Mortality In The Lives of Children With Epilepsy Mortality in CWE: Analyzing the prevalence and risk factors Kevin Jones

ICNC2024 Symposia: Addressing The Restrictions and Mortality In The Lives of Children With Epilepsy Can we prevent SUDEP Rajesh Ramachandran Nair

ICNC2024 Symposia: Pediatric Headaches With The Challenges of The New Normal Pediatric Headaches other than Migraine Farida Jan

ICNC2024 Symposia: Pediatric Headaches With The Challenges of The New Normal Chronic headaches in children and adolescents: Dilemma in diagnosis and management Shahnaz Ibrahim

Speaker: Dr. Haluk Topaloglu When: Saturday, May 31, 2025 Time: 9:00 AM EST About Topic: Paintings of children as the centre of attention or theme, from different periods and cultures in time, from thousands of years BC up until our contemporary times.

Speaker: Pr Kumaran Deiva When: Mercredi, Mai 21, 2025 Time: 7 PM CEST About Topic: La SEP de l’enfant est reconnue de plus en plus précocement grâce à l'amélioration des critères diagnostiques (2017 IPMSSG). Les traitements de fond utilisés chez l’adulte sont désormais validés chez l’enfant : le fingolimod a été le premier approuvé pour les formes pédiatriques récurrentes. D’autres biothérapies comme le natalizumab ou l’ocrelizumab sont utilisées hors AMM avec des résultats prometteurs. La prise en charge actuelle repose sur une approche précoce, individualisée et multidisciplinaire, intégrant neurologie,...